Xilio Therapeutics, Inc..
XLO.US | Research and experimental development on natural sciences and engineering
Xilio Therapeutics, Inc. is a biotechnology company focused on developing tumor-selective immuno-oncology therapies for patients with cancer. The company's product candidates are designed to unleash the power of the immune system only within the tumor microenvironment, thereby minimizing systemic to...Show More
Better Health for All
0
No relevant data was found in the provided articles to assess Xilio Therapeutics, Inc. against the 'Better Health for All' ethical value.
1
All articles contained placeholder content and explicitly stated a lack of specific, concrete information regarding the company's health impact, safety record, accessibility, or any other related metrics.
2
Fair Money & Economic Opportunity
0
No evidence available to assess Xilio Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. While executive compensation figures are available, median employee compensation is not, preventing the calculation of the CEO median pay ratio.
1
Similarly, there is no data on living wage coverage, collective bargaining, safety incident rates, pay equity, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage.
2
The articles explicitly state these data gaps for all relevant KPIs.
Fair Trade & Ethical Sourcing
0
No data relevant to XLO.US and Fair Trade & Ethical Sourcing could be extracted from the provided articles. All articles either returned a 404 error
1
or explicitly stated that no information related to the company or the ethical value was found.
2
Honest & Fair Business
0
The company has a comprehensive whistleblower policy, which includes a confidential and anonymous financial concern hotline and a secure web form for reporting complaints regarding accounting, internal accounting controls, or auditing matters.
1
This policy is communicated annually to all staff, officers, and directors, who are required to certify their receipt, reading, and understanding of the Code of Business Conduct and Ethics.
2
The Audit Committee oversees these procedures, receives a record of all complaints and concerns each fiscal quarter, and evaluates them, authorizing follow-up actions.
3
The policy also explicitly protects against retaliation for reporting concerns, unless the report is knowingly false.
4
Xilio Therapeutics has had zero financial restatements in the past five years. The board has determined that all directors, except one, are independent, meaning approximately 75% of the board is conflict-free.
5
The company has an anti-corruption policy that applies globally, prohibits bribes and kickbacks, requires compliance with the Foreign Corrupt Practices Act, and mandates compliance with its Global Anti-Corruption Policy and Policy on Gifts, Meals, Entertainment & Travel with Healthcare Professionals.
6
Kind to Animals
0
No evidence available to assess Xilio Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
Xilio Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for cancer and infectious diseases.
1
The company's core business is not related to defense or arms.
2
There is no evidence of revenue from arms or defense contracts, nor any sales to embargoed regimes.
3
The Audit Committee oversees financial reporting and internal controls, but the provided documents do not mention any board oversight of defense-related activities.
4
Similarly, there is no information regarding codified ethical red lines related to weapons or an annual review process for partners with conflict-related risks.
5
Planet-Friendly Business
0
No specific, quantitative evidence regarding Xilio Therapeutics, Inc.'s environmental performance, targets, or initiatives could be found in the provided articles.
1
The articles either contained no company-specific data or were inaccessible.
Respect for Cultures & Communities
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. While some articles mention general engagement with 'nonprofit partners'
1
or 'volunteering' in the Greater Boston area
2
, this information lacks the specificity required by the rubric, such as the number of formal partnerships with indigenous or local community groups, specific percentages of revenue reinvested, or details on cultural impact protocols or incidents. The articles primarily consist of corporate governance document lists
3
, financial filing lists
4
, or general statements that do not provide concrete data points for scoring against the defined KPIs.
Safe & Smart Tech
0
No specific, concrete evidence was found across the provided articles to assess Xilio Therapeutics, Inc. against any of the 'Safe & Smart Tech' KPIs. The articles primarily consist of SEC financial filings for the company and general industry news, none of which contain factual data points related to Xilio Therapeutics, Inc.'s data protection, cybersecurity, or AI ethics practices.
Zero Waste & Sustainable Products
0
No evidence available to assess Xilio Therapeutics, Inc. on Zero Waste & Sustainable Products.